[1]
|
中国医师协会血液科医师分会, 中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022年修订) [J]. 中华内科杂志, 2022, 61(5): 480-487.
|
[2]
|
Rajkumar, S.V. (2022) Multiple Myeloma: 2022 Update on Diagnosis, Risk Strati-fication, and Management. American Journal of Hematology, 97, 1086-1107. https://doi.org/10.1002/ajh.26590
|
[3]
|
Silberstein, J., Tuchman, S. and Grant, S.J. (2022) What Is Multiple Mye-loma? JAMA, 327, 497.
https://doi.org/10.1001/jama.2021.25306
|
[4]
|
Boise, L.H., Kaufman, J.L., Bahlis, N.J., et al. (2014) The Tao of Myeloma. Blood, 124, 1873-1879.
https://doi.org/10.1182/blood-2014-05-578732
|
[5]
|
Luo, S., Su, T., Zhou, X., et al. (2022) Chromosome 1 Insta-bility in Multiple Myeloma: Aberrant Gene Expression, Pathogenesis, and Potential Therapeutic Target. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 36, e22341. https://doi.org/10.1096/fj.202200354
|
[6]
|
Neuse, C.J., Lomas, O.C., Schliemann, C., et al. (2020) Genome Insta-bility in Multiple Myeloma. Leukemia, 34, 2887-2897.
https://doi.org/10.1038/s41375-020-0921-y
|
[7]
|
Hultcrantz, M., Yellapantula, V. and Rustad, E.H. (2020) Ge-nomic Profiling of Multiple Myeloma: New Insights and Modern Technologies. Best Practice & Research Clinical Haematology, 33, Article ID: 101153.
https://doi.org/10.1016/j.beha.2020.101153
|
[8]
|
Giri, S., Huntington, S.F., Wang, R., et al. (2020) Chromosome 1 Abnormalities and Survival of Patients with Multiple Myeloma in the Era of Novel Agents. Blood Advances, 4, 2245-2253.
https://doi.org/10.1182/bloodadvances.2019001425
|
[9]
|
Panani, A.D., Ferti, A.D., Papaxoinis, C., et al. (2004) Cytogenetic Data as a Prognostic Factor in Multiple Myeloma Patients: Involvement of 1p12 Region an Adverse Prog-nostic Factor. Anticancer Research, 24, 4141-4146.
|
[10]
|
Boyd, K.D., Ross, F.M., Walker, B.A., et al. (2011) Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Re-gions Associated with Adverse Survival. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 17, 7776-7784.
https://doi.org/10.1158/1078-0432.CCR-11-1791
|
[11]
|
Lohr, J.G., Stojanov, P., Carter, S.L., et al. (2014) Wide-spread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. Cancer Cell, 25, 91-101. https://doi.org/10.1016/j.ccr.2013.12.015
|
[12]
|
Liu, S., Chen, H., Yin, Y., et al. (2023) Inhibition of FAM46/TENT5 Activity by BCCIPα Adopting a Unique Fold. Science Advances, 9, eadf5583. https://doi.org/10.1126/sciadv.adf5583
|
[13]
|
Zhang, H., Zhang, S.-H., Hu, J.-L., et al. (2021) Structural and Func-tional Characterization of Multiple Myeloma Associated Cytoplasmic poly(A) Polymerase FAM46C. Cancer Communi-cations (London, England), 41, 615-630.
https://doi.org/10.1002/cac2.12163
|
[14]
|
Manfrini, N., Mancino, M., Miluzio, A., et al. (2020) FAM46C and FNDC3A Are Multiple Myeloma Tumor Suppressors That Act in Concert to Impair Clearing of Protein Aggregates and Autophagy. Cancer Research, 80, 4693-4706.
https://doi.org/10.1158/0008-5472.CAN-20-1357
|
[15]
|
Kanasugi, J., Hanamura, I., Ota, A., et al. (2020) Biallelic Loss of FAM46C Triggers Tumor Growth with Concomitant Activation of Akt Signaling in Multiple Myeloma Cells. Cancer Science, 111, 1663-1675.
https://doi.org/10.1111/cas.14386
|
[16]
|
Comet, I., Riising, E.M., Leblanc, B., et al. (2016) Maintaining Cell Identity: PRC2-Mediated Regulation of Transcription and Cancer. Nature Reviews. Cancer, 16, 803-810. https://doi.org/10.1038/nrc.2016.83
|
[17]
|
Perino, M., van Mierlo, G., Karemaker, I.D., et al. (2018) MTF2 Recruits Polycomb Repressive Complex 2 by Helical-Shape-Selective DNA Binding. Nature Genetics, 50, 1002-1010. https://doi.org/10.1038/s41588-018-0134-8
|
[18]
|
Saul, M.C., Majdak, P., Perez, S., et al. (2017) High Motivation for Exercise Is Associated with Altered Chromatin Regulators of Monoamine Receptor Gene Expression in the Striatum of Selectively Bred Mice. Genes, Brain, and Behavior, 16, 328-341. https://doi.org/10.1111/gbb.12347
|
[19]
|
Yang, Z., Sun, Q., Guo, J., et al. (2019) GRSF1-Mediated MIR-G-1 Promotes Malignant Behavior and Nuclear Autophagy by Directly Upregulating TMED5 and LMNB1 in Cervical Cancer Cells. Autophagy, 15, 668-685.
https://doi.org/10.1080/15548627.2018.1539590
|
[20]
|
Liu, Y., Yu, H., Yoo, S., et al. (2019) A Network Analysis of Multiple Myeloma Related Gene Signatures. Cancers, 11, 1452. https://doi.org/10.3390/cancers11101452
|
[21]
|
Yan, M., Niu, L., Liu, J., et al. (2021) circEVI5 Acts as a miR-4793-3p Sponge to Suppress the Proliferation of Gastric Cancer. Cell Death & Disease, 12, 774. https://doi.org/10.1038/s41419-021-04061-4
|
[22]
|
Małecki, J.M., Odonohue, M.-F., Kim, Y., et al. (2021) Human METTL18 Is a Histidine-Specific Methyltransferase That Targets RPL3 and Affects Ribosome Biogenesis and Function. Nucleic Acids Research, 49, 3185-3203.
https://doi.org/10.1093/nar/gkab088
|
[23]
|
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium (2023) Author Correction: Pan-Cancer Analysis of Whole Genomes. Nature, 614, E39.
|
[24]
|
Hofman, I.J.F., Patchett, S., van Duin, M., et al. (2017) Low Frequency Mutations in Ribosomal Proteins RPL10 and RPL5 in Multiple Myeloma. Haematologica, 102, e317-e320. https://doi.org/10.3324/haematol.2016.162198
|
[25]
|
Hofman, I.J.F., van Duin, M., Bruyne, E., et al. (2017) RPL5 on 1p22.1 Is Recurrently Deleted in Multiple Myeloma and Its Expression Is Linked to Bortezomib Response. Leukemia, 31, 1706-1714. https://doi.org/10.1038/leu.2016.370
|
[26]
|
Zhang, A., Huang, Z., Tao, W., et al. (2022) USP33 Deubiquitinates and Stabilizes HIF-2alpha to Promote Hypoxia Response in Glioma Stem Cells. The EMBO Journal, 41, e109187. https://doi.org/10.15252/embj.2021109187
|
[27]
|
Kitamura, H. (2023) Ubiquitin-Specific Proteases (USPs) and Metabolic Disorders. International Journal of Molecular Sciences, 24, 3219. https://doi.org/10.3390/ijms24043219
|
[28]
|
Chen, S., Liang, Y., Shen, Y., et al. (2023) lncRNA XIST/miR-129-2-3p Axis Targets CCP110 to Regulate the Proliferation, Invasion and Migration of Endometrial Cancer Cells. Experimental and Therapeutic Medicine, 25, Article No. 159. https://doi.org/10.3892/etm.2023.11858
|
[29]
|
Simicek, M., Lievens, S., Laga, M., et al. (2013) The Deubiquitylase USP33 Discriminates between RALB Functions in Autophagy and Innate Immune Response. Nature Cell Biology, 15, 1220-1230. https://doi.org/10.1038/ncb2847
|
[30]
|
Chng, W.J., Gertz, M.A., Chung, T.-H., et al. (2010) Correlation between Array-Comparative Genomic Hybridization-Defined Genomic Gains and Losses and Survival: Identification of 1p31-32 Deletion as a Prognostic Factor in Myeloma. Leukemia, 24, 833-842. https://doi.org/10.1038/leu.2010.21
|
[31]
|
Clark, N., Wu, X. and Her, C. (2013) MutS Homologues hMSH4 and hMSH5: Genetic Variations, Functions, and Implications in Human Diseases. Current Genomics, 14, 81-90. https://doi.org/10.2174/1389202911314020002
|
[32]
|
Li, L., Hao, J., Yan, C.-Q., et al. (2020) Inhibition of mi-croRNA-300 Inhibits Cell Adhesion, Migration, and Invasion of Prostate Cancer Cells by Promoting the Expression of DAB1. Cell Cycle (Georgetown, Tex.), 19, 2793-2810.
https://doi.org/10.1080/15384101.2020.1823730
|
[33]
|
Wang, H., Meng, H., Wang, J., et al. (2020) Clinical Char-acteristics and Prognostic Values of 1p32.3 Deletion Detected through Fluorescence in Situ Hybridization in Patients with Newly Diagnosed Multiple Myeloma: A Single-Center Study in China. Frontiers of Medicine, 14, 327-334. https://doi.org/10.1007/s11684-019-0712-x
|
[34]
|
Hebraud, B., Leleu, X., Lauwers-Cances, V., et al. (2014) Dele-tion of the 1p32 Region Is a Major Independent Prognostic Factor in Young Patients with Myeloma: The IFM Experi-ence on 1195 Patients. Leukemia, 28, 675-679.
https://doi.org/10.1038/leu.2013.225
|
[35]
|
Bretz, J., Garcia, J., Huang, X., et al. (2011) Noxa Mediates p18INK4c Cell-Cycle Control of Homeostasis in B Cells and Plasma Cell Precursors. Blood, 117, 2179-2188. https://doi.org/10.1182/blood-2010-06-288027
|
[36]
|
Morse, L., Chen, D., Franklin, D., et al. (1997) Induction of Cell Cycle Arrest and B Cell Terminal Differentiation by CDK Inhibitor p18(INK4c) and IL-6. Immunity, 6, 47-56. https://doi.org/10.1016/S1074-7613(00)80241-1
|
[37]
|
Kulkarni, M.S., Daggett, J.L., Bender, T.P., et al. (2002) Frequent Inactivation of the Cyclin-Dependent Kinase Inhibitor p18 by Homozygous Deletion in Multiple Myeloma Cell Lines: Ectopic p18 Expression Inhibits Growth and Induces Apoptosis. Leukemia, 16, 127-134. https://doi.org/10.1038/sj.leu.2402328
|
[38]
|
Adamia, S., Bhatt, S., Wen, K., et al. (2022) Combination Therapy Targeting Erk1/2 and CDK4/6i in Relapsed Refractory Multiple Myeloma. Leukemia, 36, 1088-1101. https://doi.org/10.1038/s41375-021-01475-z
|
[39]
|
Franz, A., Pirson, P.A., Pilger, D., et al. (2016) Chroma-tin-Associated Degradation Is Defined by UBXN-3/FAF1 to Safeguard DNA Replication Fork Progression. Nature Communications, 7, Article No. 10612.
https://doi.org/10.1038/ncomms10612
|
[40]
|
Li, Y., Wu, X., Li, J., et al. (2022) Circ_0004354 Might Compete with Circ_0040039 to Induce NPCs Death and Inflammatory Response by Targeting miR-345-3p-FAF1/TP73 Axis in Inter-vertebral Disc Degeneration. Oxidative Medicine and Cellular Longevity, 2022, Article ID: 2776440. https://doi.org/10.1155/2022/2776440
|
[41]
|
Song, S., Park, J.K., Shin, S.C., et al. (2022) The Complex of Fas-Associated Factor 1 with Hsp70 Stabilizes the Adherens Junction Integrity by Suppressing RhoA Activation. Jour-nal of Molecular Cell Biology, 14, mjac037.
https://doi.org/10.1093/jmcb/mjac037
|
[42]
|
Xie, F., Jin, K., Shao, L., et al. (2017) FAF1 Phosphorylation by AKT Accumulates TGF-β Type II Receptor and Drives Breast Cancer Metastasis. Nature Communications, 8, Article No. 15021.
https://doi.org/10.1038/ncomms15021
|
[43]
|
Omran, Z., Dalhat, M., Abdullah, O., et al. (2021) Targeting Post-Translational Modifications of the p73 Protein: A Promising Therapeutic Strategy for Tumors. Cancers, 13, 1916. https://doi.org/10.3390/cancers13081916
|
[44]
|
Schultheis, B., Krämer, A., Willer, A., et al. (1999) Analysis of p73 and p53 Gene Deletions in Multiple Myeloma. Leukemia, 13, 2099-2103. https://pubmed.ncbi.nlm.nih.gov/10602435
https://doi.org/10.1038/sj.leu.2401609
|
[45]
|
Saha, M.N., Jiang, H., Yang, Y., Reece, D. and Chang, H. (2018) Correction: PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma by Induction of p73 and Noxa. Molecular Cancer Therapeutics, 17, 1143.
https://pubmed.ncbi.nlm.nih.gov/29717080
https://doi.org/10.1158/1535-7163.MCT-18-0096
|